Franklin Resources Inc. Reduces Holdings in Sanofi $SNY

Franklin Resources Inc. reduced its stake in Sanofi (NASDAQ:SNY) by 8.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,931,758 shares of the company’s stock after selling 342,652 shares during the quarter. Franklin Resources Inc.’s holdings in Sanofi were worth $185,579,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Waterfront Wealth Inc. increased its stake in Sanofi by 0.4% during the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock valued at $2,463,000 after purchasing an additional 214 shares in the last quarter. HighPoint Advisor Group LLC lifted its stake in shares of Sanofi by 2.3% during the third quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock worth $468,000 after buying an additional 226 shares during the period. HM Payson & Co. grew its holdings in shares of Sanofi by 3.4% during the third quarter. HM Payson & Co. now owns 7,248 shares of the company’s stock valued at $342,000 after buying an additional 235 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. grew its holdings in shares of Sanofi by 4.7% during the third quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,333 shares of the company’s stock valued at $252,000 after buying an additional 238 shares during the last quarter. Finally, CreativeOne Wealth LLC increased its position in shares of Sanofi by 2.8% in the 2nd quarter. CreativeOne Wealth LLC now owns 8,980 shares of the company’s stock valued at $434,000 after acquiring an additional 241 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of research reports. Citigroup began coverage on Sanofi in a research report on Tuesday, January 27th. They set a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. Five equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $62.67.

Sanofi Stock Performance

Shares of SNY stock opened at $43.63 on Friday. Sanofi has a 52-week low of $43.34 and a 52-week high of $59.17. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The stock has a market cap of $106.41 billion, a PE ratio of 12.12, a price-to-earnings-growth ratio of 1.13 and a beta of 0.45. The business has a 50-day simple moving average of $46.94 and a 200-day simple moving average of $48.28.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.